Christina Lovato, MD
Internal Medicine · Albuquerque, NMNPI 1750420741
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.2% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $866, 8.8 times the $99 reported in 2019. Among internal medicine clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 34 payments — averaging $68.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$553
- BETA Bionics, Inc.$316
- Averitas Pharma Inc.$239
- Insulet Corporation$234
- Rhythm Pharmaceuticals, Inc.$141
- Radius Health, Inc.$135
- plus $703 from 10 others
What the payments were for
- Travel & lodging$22710%
- Food & beverage$2,09490%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 8 | $553 |
| BETA Bionics, Inc. | 3 | $316 |
| Averitas Pharma Inc. | 2 | $239 |
| Insulet Corporation | 4 | $234 |
| Rhythm Pharmaceuticals, Inc. | 2 | $141 |
| Radius Health, Inc. | 1 | $135 |
| Corcept Therapeutics | 1 | $123 |
| E.r. Squibb & Sons, L.L.C. | 1 | $120 |
| Amgen | 2 | $104 |
| Novo Nordisk | 3 | $102 |
| AbbVie | 1 | $85 |
| Ultragenyx Pharmaceutical Inc. | 1 | $80 |
| Lilly USA, LLC | 2 | $31 |
| Bayer | 1 | $22 |
| Altathera Pharmaceuticals LLC | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$860
- Qutenza$239
- Confirm Rx$227
- FREESTYLE LIBRE 3$163
- iLet Insulin Infusion Kit Inset$144
- iLet Insulin Infusion Kit Contact Detach$144
- Tymlos$135
- Omnipod$125
- Imcivree$125
- Korlym$123
- OPDIVO$120
How this compares
$2,321 in reported general payments places this provider in the 90th percentile of 578 internal medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 57 | $55,857 |
| MounjaroTirzepatide | 40 | $46,048 |
| TrulicityDulaglutide | 33 | $30,588 |
| JanuviaSitagliptin Phosphate | 18 | $19,196 |
| JardianceEmpagliflozin | 12 | $17,055 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $13,735 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $9,919 |
| Humalog Kwikpen U-100Insulin Lispro | 28 | $6,345 |
| Novolog FlexpenInsulin Aspart | 25 | $5,329 |
| NovologInsulin Aspart | 16 | $4,802 |
| SynthroidLevothyroxine Sodium | 51 | $4,177 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $3,687 |
| Levothyroxine Sodium | 249 | $3,038 |
| Insulin Glargine-Yfgn | 16 | $2,883 |
| Hydrocortisone | 67 | $2,244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $31 | $76,63573 claims |
| Novo NordiskOzempic, Novolog | $102 | $60,65973 claims |
| AbbVieSynthroid | $85 | $4,17751 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 578 internal medicine providers in New Mexico.
Other internal medicine in Albuquerque
- Edward LewieckiAlbuquerque$491K
- James AdairAlbuquerque$108K
- Gulshan ParasherAlbuquerque$66K
- Mark WalkerAlbuquerque$24K
- Joao TeixeiraAlbuquerque$18K
- Karla AlmarazAlbuquerque$18K
- David SosaAlbuquerque$11K
- Revati ReddyAlbuquerque$7K
- Ross DavidsonAlbuquerque$7K
- Edmee RodriguezAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.